Nyxoah (NYXH) Stock Price, News & Analysis

Company Overview

Nyxoah S.A. is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a disorder in which breathing repeatedly stops or becomes restricted during sleep. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s primary product is the Genio system, an implantable, leadless neurostimulation device designed to treat moderate-to-severe OSA. The system stimulates the hypoglossal nerve, which helps control the muscles of the tongue and upper airway, with the goal of preventing airway obstruction during sleep. Unlike conventional continuous positive airway pressure (CPAP) therapy, Genio is intended for patients who are unable to use or tolerate CPAP.

The Genio platform is designed to be powered and controlled by an external wearable component, allowing the implanted device to deliver therapy without an implanted battery. Nyxoah has pursued regulatory approvals and commercial expansion for the system in European and other international markets, while also developing its presence in the United States. The company is led by Chief Executive Officer Olivier Taelman.

Key Stats

• Today's Range: $1.35 to $1.38
• 50-Day Range: $1.27 to $1.76
• 52-Week Range: $1.26 to $6.87
• Volume: 36,082 shs
• Average Volume: 166,579 shs
• Market Capitalization: $52.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.26
• Consensus Rating: Hold

Nyxoah Stock Analysis - MarketRank™

Nyxoah scored higher than 73% of companies evaluated by MarketBeat, and ranked 352nd out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Nyxoah has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Nyxoah has a consensus price target of $4.26, representing about 213.4% upside from its current price of $1.36.

Amount of Analyst Coverage

Nyxoah has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nyxoah are expected to grow in the coming year, from ($1.44) to ($0.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nyxoah is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nyxoah is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nyxoah has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.00% of the float of Nyxoah has been sold short.

Short Interest Ratio / Days to Cover

Nyxoah has a short interest ratio ("days to cover") of 1.53, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nyxoah has recently increased by 19.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nyxoah does not currently pay a dividend.

Dividend Growth

Nyxoah does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.86

News Sentiment

Nyxoah has a news sentiment score of 1.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Nyxoah this week, compared to 3 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nyxoah insiders have not sold or bought any company stock.

Percentage Held by Institutions

Nyxoah has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NYXH
• CIK: 1857190
• Web: www.nyxoah.com
• Phone: 321-022-2355
• Fax: 321-045-9075
• Employees: 154
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Nyxoah: $4.26
• High Price Target: $6.00
• Low Price Target: $2.31
• Potential Upside/Downside: +213.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$101.92 million
• Net Margins: -443.16%
• Pretax Margin: -436.49%
• Return on Equity: -178.90%
• Return on Assets: -81.83%

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 2.38
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: $11.33 million
• Price / Sales: 4.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.43 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 38,760,000
• Free Float: N/A
• Market Cap: $52.71 million
• Optionable: Not Optionable
• Beta: 1.65